

REPROS THERAPEUTICS INC.

Form 8-K

January 12, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): January 8, 2007  
Repos Therapeutics Inc.  
(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction of  
incorporation or organization)**

**001-15281  
(Commission File Number)**

**76-0233274  
(I.R.S. Employer Identification  
No.)**

**2408 Timberloch Place, Suite B-7  
The Woodlands, Texas 77380  
(Address of principal executive offices and zip code)  
(281) 719-3400**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On January 8, 2007, the Compensation Committee of the Board of Directors of Repros Therapeutics Inc. ( Repros ) approved a base salary increase effective January 1, 2007 of 7% for Joseph S. Podolski, the Company s President and Chief Executive Officer and Louis Ploth, Jr., the Company s Vice President, Business Development and Chief Financial Officer. Mr. Podolski will now receive an annual salary of approximately \$354,000 and Mr. Ploth will receive an annual salary of approximately \$224,000.

In addition, each of Messrs. Podolski and Ploth received options to purchase up to 50,000 shares and 20,000 shares, respectively, of the Company s common stock at an exercise price of \$12.26, which is equal to the price on the close of business on the date of grant. The options will each vest at a rate of 1/12<sup>th</sup> per quarter over a period of 3 years.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: January 12, 2007.

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Vice President, Business Development  
and Chief Financial Officer